VivoSeq
Oncology

Cancer of the Head and Neck

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Cancer of the Head and Neck is an early-stage landscape with 0 programs across 3 companies. The most active players are Trans Tasman Radiation Oncology Group, Mirror Biologics, Inc., Radiation Therapy Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

85/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Trans Tasman Radiation Oncology Group

0 programs

PreclinicalM

Mirror Biologics, Inc.

0 programs

PreclinicalRadiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

16

clinical trials

Completed11 · 69%
Terminated2 · 13%
Active, not recruiting1 · 6%
Unknown status1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
Active, not recruiting·—·Phase 1·NCT02474368·21 enrolled
The FORCE Trial Pilot: Fish Oil-enriched Nutrition for Radiotherapy in Cancer of the hEad and Neck
Not yet recruiting·—·Phase 1/2·NCT07180576·15 enrolled
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00004865
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck
Completed·TTrans Tasman Radiation Oncology Group·Phase 3·NCT00193895·321 enrolled
Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00017498·21 enrolled
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00006361
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck
Completed·MMassachusetts General Hospital·Phase 1·NCT00513383·34 enrolled
Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and Neck
Completed·UUniversity of Iowa·Phase 2·NCT01065844·15 enrolled
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck
Completed·MMirror Biologics, Inc.·Phase 2·NCT01998542·12 enrolled
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Completed·—·Phase 1·NCT00005647·12 enrolled
Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 2·NCT00002932·60 enrolled
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck
Completed·National Cancer Institute (NCI)·Phase 1·NCT00011778·25 enrolled
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
Completed·UUniversity of Chicago·Phase 2·NCT00015964·51 enrolled
Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck
Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 1·NCT02429089·21 enrolled
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
Terminated·—·Phase 1/2·NCT00570674·29 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)